Lenalidomide 100 mg | ≥98% LKT Laboratories, Inc. Thalidomide derivative; cereblon and TNF-α inhibitor. More Information Supplier Page × Lenalidomide
Lenalidomide 50 mg | ≥98% LKT Laboratories, Inc. Thalidomide derivative; cereblon and TNF-α inhibitor. More Information Supplier Page × Lenalidomide
Bosutinib, structural isomer 100 mg | ≥98% LKT Laboratories, Inc. Bosutinib isomer; Src and Abl inhibitor. More Information Supplier Page × Bosutinib, structural isomer
Bosutinib, structural isomer 25 mg | ≥98% LKT Laboratories, Inc. Bosutinib isomer; Src and Abl inhibitor. More Information Supplier Page × Bosutinib, structural isomer
Bosutinib, structural isomer 10 mg | ≥98% LKT Laboratories, Inc. Bosutinib isomer; Src and Abl inhibitor. More Information Supplier Page × Bosutinib, structural isomer
Crizotinib 100 mg | ≥98% LKT Laboratories, Inc. ALK, ROS1, c-MET inhibitor. More Information Supplier Page × Crizotinib
Tivozanib 5 mg | ≥98% LKT Laboratories, Inc. VEGFR1/2/3, c-Kit, PDGFR inhibitor. More Information Supplier Page × Tivozanib
Cabozantinib 100 mg | ≥98% LKT Laboratories, Inc. VEGFR2, c-Met, RET inhibitor. More Information Supplier Page × Cabozantinib
Cabozantinib 25 mg | ≥98% LKT Laboratories, Inc. VEGFR2, c-Met, RET inhibitor. More Information Supplier Page × Cabozantinib
Cabozantinib 10 mg | ≥98% LKT Laboratories, Inc. VEGFR2, c-Met, RET inhibitor. More Information Supplier Page × Cabozantinib
